Cosentyx
Generic Name
Secukinumab
Manufacturer
Novartis Pharmaceuticals Corporation
Country
Switzerland (originator), various manufacturing sites globally
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| cosentyx 150 mg injection | ৳ 21,990.00 | N/A |
Description
Overview of the medicine
Cosentyx (secukinumab) is a human monoclonal antibody that selectively targets the interleukin-17A (IL-17A) cytokine. It is used to treat various autoimmune inflammatory diseases.
Uses & Indications
Dosage
Adults
Plaque Psoriasis: 300 mg (two 150 mg injections) subcutaneously at Weeks 0, 1, 2, 3, and 4, then 300 mg every 4 weeks. Psoriatic Arthritis/Ankylosing Spondylitis/Non-radiographic axial spondyloarthritis: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, then 150 mg every 4 weeks. Hidradenitis Suppurativa: 300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, then 300 mg every 2 weeks.
Elderly
No specific dose adjustment required; use with caution due to higher incidence of comorbidities.
Renal_impairment
No specific studies have been conducted; dose adjustment not expected to be necessary.
How to Take
Subcutaneous injection. Administer into the thigh, abdomen, or upper arm. Rotate injection sites. Do not inject into skin that is tender, bruised, red, scaly, or hard.
Mechanism of Action
Secukinumab binds selectively to the IL-17A cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine involved in normal inflammatory and immune responses. Secukinumab inhibits the release of pro-inflammatory cytokines and chemokines.
Pharmacokinetics
Onset
Clinical improvement can be observed as early as 3 weeks for some indications.
Excretion
Not specifically studied; typically involves proteolysis and renal excretion of small peptides.
Half life
Approximately 27 days
Absorption
Peak serum concentrations are reached in 5-6 days after a single subcutaneous dose. Bioavailability is approximately 73%.
Metabolism
Expected to be degraded into small peptides and amino acids via catabolic pathways, like endogenous immunoglobulins.
Side Effects
Contraindications
- •Hypersensitivity to secukinumab or any of the excipients
- •Active severe infection
Drug Interactions
Live vaccines
Avoid co-administration with live vaccines; insufficient data on co-administration with non-live vaccines.
Immunosuppressants (e.g., methotrexate, cyclosporine)
No significant pharmacokinetic interactions; caution advised as combined immunosuppression may increase infection risk.
Storage
Store in a refrigerator (2°C-8°C / 36°F-46°F). Do not freeze. Keep the syringe/pen in the outer carton to protect from light. Do not shake.
Overdose
In clinical trials, doses up to 30 mg/kg (approx. 2000-3000 mg) intravenously did not result in dose-limiting toxicity. In case of overdose, monitor for signs and symptoms of adverse reactions and provide symptomatic treatment.
Pregnancy & Lactation
Pregnancy Category B. Use only if clearly needed and the potential benefit outweighs the potential risk to the fetus. It is not known whether secukinumab is excreted in human milk; caution advised.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years, refer to product labeling for exact expiry date.
Availability
Hospitals, Specialty Pharmacies
Approval Status
FDA Approved
Patent Status
Patented
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in